Multiple Sclerosis: key endpoint results by drug
The key endpoints of Multiple Sclerosis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Multiple Sclerosis page.
Annualised relapse rate
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | 0.1 | 0.1 | ±0 | wk 24 · n 42 | NCT01116427 Phase 2, secondary |
| Alemtuzumab | 0.3 | 0.5 (Interferon Beta-1a) | — | 12 mg · wk 104 · n 426 | NCT00548405 Phase 3, primary |
| Cladribine (MAVENCLAD®) | 0.1 | 0.3 | −0.2 | 5.25 mg/kg · wk 96 · n 456 | NCT00213135 Phase 3, primary |
| Copaxone | 0.3 | 0.4 | −0.1 | wk 104 · n 82 | NCT00451204 Phase 2, primary |
| Dimethyl fumarate (Tecfidera) | 0.2 | 0.4 | −0.2 | 240 mg twice daily · wk 104 · n 359 | NCT00451451 Phase 3, primary |
| fingolimod (Gilenya) | 0.2 | 0.4 | −0.2 | 0.5 mg · wk 104 · n 425 | NCT00289978 Phase 3, primary |
| Interferon beta-1b | 0.2 | 0.3 | −0.1 | n 292 | NCT00185211 Phase 3, secondary |
| natalizumab | 0.5 | 1.7 | −1.2 | wk 24 · n 9 | NCT01440101 Phase 2/3, secondary |
| Ocrelizumab | 0.2 | 0.3 (Interferon Beta-1a) | — | wk 96 · n 410 | NCT01247324 Phase 3, primary |
| Ofatumumab | 0.1 | 0.3 (TER) | — | 20 mg · n 469 | NCT02792231 Phase 3, primary |
| ozanimod | 0.2 | 0.3 (Interferon Beta-1a) | — | 1 mg · wk 96 · n 433 | NCT02047734 Phase 3, primary |
| peginterferon beta-1a | 0.3 | 0.4 | −0.1 | every 4 weeks · wk 52 · n 500 | NCT00906399 Phase 3, primary |
| Ponesimod | 0.2 | 0.3 (Teriflunomide) | — | 20 mg · wk 108 · n 567 | NCT02425644 Phase 3, primary |
| Tolebrutinib | 0.1 | 0.1 (Teriflunomide) | — | 60 mg · wk 208 · n 486 | NCT04410978 Phase 3, primary |
| Ublituximab | 0.1 | 0.2 (Teriflunomide) | — | wk 96 · n 271 | NCT03277261 Phase 3, primary |
Drugs checked with no result here: 34 not reported, 9 not posted, 8 trial running.
New or enlarging T2 lesions
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| fingolimod (Gilenya) | 2.5 | 9.8 | −7.3 | 0.5 mg · wk 104 · n 370 | NCT00289978 Phase 3, secondary |
| natalizumab | 0.3 | 1.1 | −0.8 | wk 24 · n 47 | NCT01440101 Phase 2/3, secondary |
| Ocrelizumab | 430 | 1916 (Interferon Beta-1a) | — | wk 96 · n 410 | NCT01247324 Phase 3, secondary |
| ozanimod | 0.8 | 9 | −8.2 | 1 mg · wk 24 · n 83 | NCT01628393 Phase 2/3, secondary |
| peginterferon beta-1a | 7.9 | 10.9 | −3 | every 4 weeks · wk 52 · n 462 | NCT00906399 Phase 3, secondary |
| Tolebrutinib | 0.2 | 2.1 | −1.9 | 60 mg · n 31 | NCT03889639 Phase 2, secondary |
Drugs checked with no result here: 37 not reported, 13 not posted, 10 trial running.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 66 approved or late-stage drugs with a featured trial in Multiple Sclerosis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-19. How results are chosen: methodology.